Treace Medical Concepts, Inc. (TMCI)

Market Cap	359.82M
Revenue (ttm)	210.82M
Net Income (ttm)	-52.99M
Shares Out	62.90M
EPS (ttm)	-0.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	259,679
Open	5.65
Previous Close	5.65
Day's Range	5.60 - 5.85
52-Week Range	4.54 - 10.79
Beta	0.69
Analysts	Hold
Price Target	9.42 (+64.69%)
Earnings Date	Aug 5, 2025

About TMCI

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adduc...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 23, 2021
• Employees: 477
• Stock Exchange: NASDAQ
• Ticker Symbol: TMCI
• Website: https://www.treace.com

Financial Performance

In 2024, Treace Medical Concepts's revenue was $209.36 million, an increase of 11.89% compared to the previous year's $187.12 million. Losses were -$55.74 million, 12.6% more than in 2023.

Analyst Summary

According to 5 analysts, the average rating for TMCI stock is "Hold." The 12-month stock price target is $9.42, which is an increase of 64.69% from the latest price.

Price Target

$9.42

(64.69% upside)

Analyst Consensus: Hold